骨粗しょう症薬の世界市場-2023年～2030年

市場概要

骨粗しょう症薬の世界市場は、2022年に140億6,640万米ドルに達し、2030年には193億3,660万米ドルに達する好成長が予測されています。骨粗しょう症薬の世界市場は、予測期間中（2023～2030年）に4.1%のCAGRを示すと予測されています。

骨粗しょう症薬の世界市場は、月経後骨粗鬆症の有病率の増加、治療パイプラインの規模拡大、バイオ医薬品企業による支出、早期発見のためのより高度な診断法の確立などの要因により拡大しています。

世界の骨粗しょう症薬市場は、骨粗しょう症薬の調査研究の増加、新規製品の承認取得の増加、高齢者人口の増加、技術的に進歩した新しい治療法などの要因によっても拡大しています。

市場力学

バイオテクノロジー企業や製薬企業による研究開発投資の増加が骨粗しょう症薬市場の成長を牽引

骨粗しょう症薬に関する調査研究の増加、大手バイオ医薬品企業による投資の拡大、高齢者人口の増加、革新的で技術的に高度な新しい治療法などが、骨粗しょう症薬の世界市場の成長に寄与しています。

例えば、2023年4月、ヴァンアンデル研究所は、科学者たちが骨密度減少の原因となる重要な因子を特定したという報告書を発表しました。

調査によると、KDM5Cと呼ばれるエピジェネティック・モジュレーターが失われると、マウスの骨量は維持されます。KDM5Cはエピジェネティックな"マーク"を変化させることで機能します。これはDNAの命令が適切な時と場所で使われるようにする"オン"と"オフ"のスイッチに似ています。

臨床試験の増加と老年人口の増加がメーカーに有利な機会をもたらす

主要企業が最先端の技術改良のための研究開発能力に臨床試験のために多額の投資を行っているため、市場開拓の機会が生まれています。市場に影響を与えるもう一つの動向は、老年人口における骨粗鬆症治療への需要の高まりです。2021年のアメリカ地域調査によると、国内人口の16.8％、55,892,014人が65歳以上でした。

さらに、研究者は骨粗鬆症治療のためのさまざまな臨床試験を実施しています。ラディアス・ヘルス社の声明によると、2022年10月、アバロパラチドとプラセボを比較した第3相骨粗鬆症男性治療用アバロパラチド臨床試験（NCT03512262）から得られたデータがJournal of Bone and Mineral Research誌に掲載されました。

TYMLOS（アバロパラチド）と呼ばれるヒト副甲状腺ホルモン結合ペプチド類似体は、骨折リスクの高い閉経後骨粗鬆症女性の管理薬としてすでに承認されています。

骨髄指向性薬による治療率の低さが市場の成長を妨げる

しかし、骨粗しょう症薬の世界市場は、先進薬の法外な価格、後期段階での探索的候補薬の不能、骨粗鬆症疾患に対する骨指向性薬による治療率の低さなどにより、予測期間中に制約を受ける可能性があります。

内分泌学会の年次総会であるENDO2021で発表された研究結果によると、骨粗鬆症の重大な副作用の一つである股関節骨折を米国で発症した経済的保険加入患者のうち、骨折後最初の2四半期に骨粗鬆症治療を受けていたのは10人に1人以下でした。これらの要因は、予想される期間における市場拡大を妨げています。

COVID-19影響分析

COVID-19分析には、Pre-COVIDシナリオ、COVIDシナリオ、Post-COVIDシナリオに加え、価格力学（パンデミック中およびパンデミック後の価格変動を含み、COVID前のシナリオと比較評価）、需給スペクトラム（取引制限、ロックダウン、およびその後の問題による需給のシフト）、政府の取り組み（政府機関による市場、産業、セクターの再活性化の取り組み）、メーカーの戦略的取り組みが含まれます。

ロシア・ウクライナ紛争の影響分析

ロシア・ウクライナ紛争は、同地域の主要市場プレーヤーの数が少ないことから、世界の骨粗しょう症薬市場への影響は低いと推定されます。しかし、原材料の輸出入の影響は、予測期間中、世界の骨粗しょう症薬市場の成長にほとんど影響を与えないと予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • バイオテクノロジー企業や製薬企業による研究開発投資の増加
    • 骨粗鬆症患者の増加
  • 抑制要因
    • 骨粗しょう症薬の普及率の低さ
  • 機会
    • 臨床試験の増加と高齢人口の増加
  • 影響分析

第5章 産業分析

• ポーターの5フォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 COVID-19分析

第7章 薬剤クラス別

• ビスフォスフォネート
• RANKリガンド阻害薬
• 選択的エストロゲン受容体モジュレーター
• 副甲状腺ホルモンアナログ
• ストロンチウム
• カルシトニン
• 抗スクレロスチン薬
• その他

第8章 製品タイプ別

• ブランド
• ジェネリック医薬品

第9章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • その他アジア太平洋地域
• 中東およびアフリカ
  • 主な地域別ダイナミクス

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第12章 企業プロファイル

• F. Hoffmann-La Roche
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Novartis AG
• Merck & Co. Inc.
• Pfizer Inc.
• Eli Lilly and Co.（Lilly）
• Amgen Inc.
• Radius Health, Inc.
• Teva Pharmaceutical Industries Ltd.
• GSK Plc
• AbbVie Inc.

第13章 付録

Market Overview

The Global Osteoporosis Drugs Market reached US$ 14,066.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 19,336.6 million by 2030. The global osteoporosis drugs market is expected to exhibit a CAGR of 4.1% during the forecast period (2023-2030).

The global market for osteoporosis medications is expanding as a result of factors including the increasing prevalence of post menstruation osteoporosis, the growing size of the therapeutic pipeline, expenditures by biopharmaceutical companies and the creation of more sophisticated diagnostics for early detection.

The global osteoporosis drugs market is also expanding owing to the the increasing research studies for osteoporosis drugs, rising regulatory approvals for novel products, rising geriatric population, new novel technologically advanced therapies.

Market Dynamics

The Growing Investments in Research and Development by Biotechnology and Pharmaceutical Companies Drive the Growth of the Osteoporosis Drugs Market

The growing number of research studies on osteoporosis medicines, the growing investments by major biopharmaceutical companies, an increase in the population of older people, and new, innovative, technologically sophisticated therapies are all contributing to the growth of the global market for osteoporosis drugs.

For instance in April 2023, Van Andel Research Institute published a report which reported that the scientists have identified a crucial factor that contributes to decreased bone density; this finding may result in more effective medicines with fewer adverse effects for women with osteoporosis.

According to the research, mice's bone mass is preserved when an epigenetic modulator called KDM5C is lost. KDM5C functions by changing epigenetic "marks," which are similar to "on" and "off" switches that make sure the DNA instructions are used at the appropriate time and location.

Growing Clinical Trials and Rising Geriatric Population Creates Lucrative Opportunities for Manufacturers

Due to key players' significant investments for clinical trials in research and development capabilities for cutting-edge technical improvements, there is a developing market opportunity. Another trend influencing the market is the growing demand for osteoporosis treatment is geriatric population. According to the 2021 American Community Survey, 16.8% of the country's population, or 55,892,014 persons, was 65 years of age or older.

Furthermore, researchers are conducting various clinical trials for osteoporosis treatment. In October 2022, data obtained from the Phase 3 Abaloparatide for the treating men with Osteoporosis clinical trial (NCT03512262) comparing abaloparatide to a placebo has been published in the Journal of Bone and Mineral Research, according to a statement from Radius Health, Inc.

A human parathyroid hormone-linked peptide analog called TYMLOS (abaloparatide) is already approved for the management of postmenopausal women with osteoporosis who are at a high risk of fracture.

A Low Rate of Treatment With Bone-Directed Medications will Hamper the Growth of the Market

The global marketplace for osteoporosis drugs, however, may be constrained over the projected period due to the prohibitive prices of advanced medications, the inability of exploratory candidates during the latter stages, and the low rate of treatment with bone-directed medicines for osteoporosis disease.

Less than one in ten economically insured patients in the United States who got a hip fracture, one of the highly serious adverse effects of osteoporosis, obtained any osteoporosis medical treatment during the first two calendar quarters of their fracture, according to a study whose results were presented at the Endocrine Society's annual meeting, ENDO 2021. These factors prevent market expansion over the expected time period.

COVID-19 Impact Analysis

The COVID-19 Analysis includes the Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario in addition to Pricing Dynamics (Including pricing change during and after the pandemic evaluating it with pre-COVID scenarios), Demand-Supply Spectrum (Shift in demand and supply due to trading restrictions, lockdown, and afterward issues), Government Initiatives (Initiatives to reactivate a market, industry, or sector by Government Bodies), and Manufacturers Strategic Initiatives.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global osteoporosis drugs market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global osteoporosis drugs market growth over the forecast period.

Segment Analysis

The global osteoporosis drugs market is segmented based on drug class, product type, distribution channel and region.

Hospital Pharmacy from Distribution Channel Segment Accounts for 42.1% of Market Share Owing to Rising Hospital Admissions

The ultimate objective of hospital pharmacy is to maintain and enhance patient drug administration at all times. Hospital pharmacists' primary duty is to regulate the use of medications in hospitals and other healthcare facilities. Through the prescription, purchasing, distribution, monitoring, and review of drugs, one of the objectives is to improve patient outcomes.

Hospital pharmacies will see an increase in demand benefits including teaching patients how to take their prescriptions, giving them in an emergency, and aiding with specialized medical treatment, like for cancer patients.

If necessary, the hospital pharmacy can assist with modifying dosages or altering drugs. Finding medicine formulations that the patient can use and making sure the container can be read and opened with ease. identifying potential health issues unrelated to osteoporosis. Hence above mentioned factors prove that hospital pharmacy will be the largest market shareholder.

Geographical Analysis

North America Accounted for Approximately 38.7% of the Market Share Owing to the Strong Presence of Major Players and Increasing Technological Advancements

Manufacturers have chances to expand their operations in this region because of the rising demand for osteoporosis drugs for advancements in North America. The area has many producers and suppliers, and its rapid economic development has raised industrial production of osteoporosis drugs, which has increased the demand.

North America has a large number of producers and suppliers, and as a result of the swift economic development of the area, industrial production has increased, fueling the demand of osteoporosis drugs. Rising new product launches for using in men and women with osteoporosis will drive the market growth.

Growth is also fueled by the rising technological advancements, regulatory approvals and novel product launches. Reseaerchers are becoming more aware of various kinds of diagnostics or treatment approaches for osteoporosis, leading to the expansion of the market in this region. These factors shows the dominance of North America.

Competitive Landscape

The major global players in the osteoporosis drugs market include: F. Hoffmann-La Roche, Novartis AG, Merck & Co. Inc., Pfizer Inc., GSK Plc, Eli Lily and Co., Amgen Inc., AbbVie Inc., Teva Pharmaceuticals Industries Ltd. and Radius Health Inc. among others.

Why Purchase the Report?

• To visualize the global osteoporosis drugs market segmentation based on drug class, product type, distribution channel and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of osteoporosis drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global osteoporosis drugs market report would provide approximately 53 tables, 54 figures and 195 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drug Class
• 3.2. Snippet by Product Type
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. The growing investments in research and development by biotechnology and pharmaceutical companies
    • 4.1.1.2. Increasing incidences of osteoporosis
  • 4.1.2. Restraints
    • 4.1.2.1. A low rate of treatment with bone-directed medications
  • 4.1.3. Opportunity
    • 4.1.3.1. Growing clinical trials and rising geriatric population
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Post COVID-19 & Future Scenario
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Drug Class

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 7.1.2. Market Attractiveness Index, By Drug Class
• 7.2. Bisphosphonates *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. RANK Ligand Inhibitors
• 7.4. Selective Estrogen Receptor Modulators
• 7.5. Parathyroid Hormone Analog
• 7.6. Strontium
• 7.7. Calcitonin
• 7.8. Anti-Sclerostin
• 7.9. Others

8. By Product Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.1.2. Market Attractiveness Index, By Product Type
• 8.2. Branded *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Generics

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacy *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacy
• 9.4. Online Pharmacy

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. The U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. The U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan

Australia

• 10.5.6.4. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. F. Hoffmann-La Roche *
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Novartis AG
• 12.3. Merck & Co. Inc.
• 12.4. Pfizer Inc.
• 12.5. Eli Lilly and Co. (Lilly)
• 12.6. Amgen Inc.
• 12.7. Radius Health, Inc.
• 12.8. Teva Pharmaceutical Industries Ltd.
• 12.9. GSK Plc
• 12.10. AbbVie Inc.

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us